Abstract: The present disclosure relates to methods and compositions useful for the identification of a ryanodine receptor modulator binding site in ryanodine receptor type 1 (RyR1). The present disclosure also provides compositions useful for the analysis of the ryanodine receptor modulator binding site in RyR1 via cryoEM. The present disclosure further provides computational methods for identifying compounds that bind to RyR1.

Abstract: The present disclosure relates to methods and compositions useful for the identification of a ryanodine receptor modulator binding site in ryanodine receptor type 2 (RyR2). The present disclosure also provides compositions useful for the analysis of the ryanodine receptor modulator binding site in RyR2 via cryo-EM. The present disclosure further provides computational methods for identifying compounds that bind to RyR2.

Abstract: A method for treating cognitive dysfunction by administering a therapeutically effective amount of a calcium channel stabilizer to a subject in need thereof. The preferred calcium channel stabilizers include a 1,4-benzothiazepine moiety, including those of the general structural formula: The method is useful with various types of respiratory viruses, including for coronaviruses, COVID, SARS and MERS. The method of treatment increases RyR2-Castabin2 binding in cardiac muscle of the subject while also decreasing open probability (Po) of RyR2 protein in the subject. All of these effects act to at least partially offset cognitive dysfunctions such as a deficit in attention, executive functioning, language, processing speed, memory, and combinations thereof.

Abstract: This invention provides a stent for implantation in a blood vessel or other tissue, wherein the stent is coated with or contains C3 exoenzyme, a chimeric version thereof or an inhibitor of RhoA. This invention also provides a method for treating or inhibiting the onset of restenosis in a subject which comprises implanting one of the instant stents in the subject's blood vessel.

Abstract: The present invention relates to compositions containing an mTOR inhibitor, such as rapamycin or a rapamycin derivative, in combination with a PI3 kinase inhibitor and/or a leptin inhibitor, intraluminal devices configured to release such compositions, and methods for the treatment and/or prevention of intimal hyperplasia, vascular stenosis and/or restenosis comprising delivery of such compositions or intraluminal devices to subjects in need thereof. The compositions, intraluminal devices, and methods of the invention are particularly well-suited for the treatment or prevention of vascular stenosis and restenosis in obese and diabetic subjects.

Abstract: The present invention provides screening methods for identifying agents that enhance binding of a ryanodine receptor and its corresponding FKBP protein, such agents to be used in treating diseases associated with ryanodine receptors.

Abstract: This invention provides a stent for implantation in a blood vessel or other tissue, wherein the stent is coated with or contains C3 exoenzyme, a chimeric version thereof or an inhibitor of RhoA. This invention also provides a method for treating or inhibiting the onset of restenosis in a subject which comprises implanting one of the instant stents in the subject's blood vessel.

Abstract: This invention provides a stent for implantation in a blood vessel or other tissue, wherein the stent is coated with or contains C3 exoenzyme, a chimeric version thereof or an inhibitor of RhoA. This invention also provides a method for treating or inhibiting the onset of restenosis in a subject which comprises implanting one of the instant stents in the subject's blood vessel.

Abstract: This invention provides methods of treating defective skeletal muscle function during heart failure and methods for identifying compounds useful in such treatments.

Abstract: This invention provides methods of treating defective skeletal muscle function during heart failure and methods for identifying compounds useful in such treatments.

Abstract: This invention provides methods for treating a subject afflicted with atrial tachyarrhythmia and methods for inhibiting the onset of atrial tachyarrhythmia. This invention also provides methods for treating a subject afflicted with exercise-induced or stress-induced cardiac arrhythmia and methods for inhibiting the onset of exercise-induced or stress-induced cardiac arrhythmia.

Abstract: This invention is directed to a stent for implantation in a blood vessel, wherein the stent is coated with Y-27632. The invention also provides a method of treating restenosis in a subject which comprises implanting in the subject a stent coated with Y-27632.

Abstract: This invention provides methods of regulating contraction of a subject's heart and of treating heart failure and cardiac arrhythmia. This invention also provides methods of obtaining compounds that bind to, and activate or inhibit the activation of a type 2 ryanodine (RyR2) receptor, and methods for screening for compounds that alleviate heart disease.

Abstract: This invention provides a stent for implantation in a blood vessel or other tissue, wherein the stent is coated with or contains C3 exoenzyme, a chimeric version thereof or an inhibitor of RhoA. This invention also provides a method for treating or inhibiting the onset of restenosis in a subject which comprises implanting one of the instant stents in the subject's blood vessel.

Abstract: This invention provides methods of preventing cellular migration and of treating cardiovascular diseases and tumor metastasis by increasing the intracellular concentration of cyclin-dependent kinase inhibitor p27 or C3 exoenzyme or by decreasing the intracellular concentration of Rho-kinase, and methods of identifying chemical compounds for use in such treatments.

Abstract: This invention provides methods of regulating contraction of a subject's heart and of treating heart failure and cardiac arrhythmia. This invention also provides methods of obtaining compounds that bind to, and activate or inhibit the activation of a type 2 ryanodine (RyR2) receptor, and methods for screening for compounds that alleviate heart disease.

Abstract: This invention provides methods of preventing cellular migration and of treating cardiovascular diseases and tumor metastasis by increasing cyclin-dependent kinase inhibitor p27 activity, and methods of identifying chemical compounds for use in such treatments.

Abstract: A user-authentication system includes an authorized user device (AUD) for transmission of dtmf tones to a user-verification system (UVS) over a telephone network, where user-verification is performed and authorized users are granted access to a desired service. In a memory module of the AUD, a plurality of passphrases and identifying data are stored for subsequent transmission to the UVS. The compensating system comprises a pair of tone devices that generate low frequency tones and high frequency tones, respective that are amplified to different amplification levels. The amplification levels compensate for the low and high frequency tone transmission characteristics associated with different microphones in use in a public telephone system. The systems further performs channel normalization with the user-activated AUD and the UVS. Tone signals representative of the access telephone number transmitted by the AUD to reach the UVS, have a reference amplitude of zero.

Abstract: A user-authentication system includes an authorized user device (AUD) for transmission of DTMF tones to a user-verification system (UVS) over a telephone network, where user-verification is performed and authorized users are granted access to a desired service. In a memory module of the AUD, a plurality of passphrases and identifying data are stored for subsequent transmission to the UVS. The UVS includes a memory module for receiving and storing the passphrases and identifying data, and a processor for determining whether user-stated passphrases correspond to the stored passphrases, and for prompting the user with knowledge-based questions and determining whether the identifying data corresponds to answers given by a user in response to the knowledge-based questions.

Abstract: A user-authentication system includes an authorized user device (AUD) for transmission of dtmf tones to a user-verification system (UVS) over a telephone network, where user-verification is performed and authorized users are granted access to a desired service. In a memory module of the AUD, a plurality of passphrases and identifying data are stored for subsequent transmission to the UVS. The UVS includes a memory module for receiving and storing the passphrases and identifying data, and a processor for determining whether user-stated passphrases correspond to the stored passphrases, and for prompting the user with knowledge-based questions and determining whether the identifying data corresponds to answers given by a user in response to the knowledge-based questions.